We also identified a large number of NOTCH2, NOTCH2NL, and FANCD2 mutations, much higher than the mutation rates reported by COSMIC in NSCLC (3%, 0.64%, and 0.94%, respectively). This evidence concerns the gene FANCD2 and non-small cell lung carcinoma.